Weiss Multi Strategy Advisers LLC Madrigal Pharmaceuticals, Inc. Transaction History

Weiss Multi Strategy Advisers LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $75,250 - $148,206	625 Added 3.58%	18,060 $4.18 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $793,727 - $1.23 Million	5,435 Added 45.29%	17,435 $2.55 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $643,241 - $984,360	3,155 Added 35.67%	12,000 $2.77 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $1.64 Million - $2.18 Million	7,106 Added 408.63%	8,845 $2.14 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $101,540 - $515,683	1,739 New	1,739 $505,000
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $280,392 - $392,658	-4,200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $353,976 - $497,700	4,200 New	4,200 $383,000
Q3 2018 Nov 14, 2018	SELL	$207.3 - $300.31 $787,740 - $1.14 Million	-3,800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $385,890 - $1.19 Million	3,800 New	3,800 $1.06 Million

295

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.58B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.